AKT1 and neoplasm: Similarly, nanoparticle-based delivery systems can be designed to selectively deliver PI3K-AKT pathway inhibitors to tumor cells (Sandhiutami et al., 2020; Du A. et al., 2022; Wang R. et al., 2022; Sanaei et al., 2022).